Get notified of page updates

Personal Story: A young woman's story of genetic testing and risk-reducing mastectomy

Printer Friendly Page Read the Original Article

Contents

At a glance Questions for your doctor
What do experts say?     Resources                          

 

ARTICLE AT A GLANCE

This article is about:

a well-written story about Alejandra Campoverdi, a young women and advocate with a  mutation.

A family history of breast cancer led to genetic testing

Alejandra Campoverdi comes from a family with many cases of breast cancer. While her mother and two aunts are survivors, both her grandmother and great-grandmother died of breast cancer.

Given her extensive family history, Alejandra chose to have genetic testing for mutations in genes that increase breast cancer risk.

She wasn’t surprised when she was told that she had a  mutation:     

"I remember when the nurse came in to tell me that I’d tested positive. The first thing out of my mouth was, ‘I know,’ because I did. My intuition, coupled with my family history, all but assured me this would be the case."

Women who test positive for a or other have a very high risk for breast, ovarian, and other cancers. There are medical options for managing these risks. 

What do the experts say?

Genetic testing
Experts recommend speaking with a health care provider with advanced training in genetics to determine if genetic testing is right for you. These experts can help make the decision about genetic testing easier. The FORCE website has resources for finding a genetics expert

Breast cancer risk
According to experts, for women with a gene mutation like Ms. Campoverdi, the lifetime risk for breast cancer is up to 70% compared to 13% in women without an . Because of this high risk, women with a gene mutation in or other genes associated with breast cancer risk have screening and risk-reducing options for managing this risk.

The National Comprehensive Cancer Network (NCCN) is a network of cancer centers that set national guidelines for cancer care. NCCN has guidelines for genetic testing and cancer risk management for breast cancer due to an . These guidelines cover:

  • enhanced breast screening
  • medications to lower cancer risk
  • risk-reducing mastectomy 

Other cancer risks
People who test positive for a gene mutation may have increased risk for other cancers.

Women with a mutation like Ms. Campoverdi have an increased risk of ovarian cancer. NCCN has guidelines for ovarian cancer risk management. Ms. Campoverdi chose to have ovarian cancer screening using a blood test known as CA 125. The use and accuracy of this test for detection of ovarian cancer is  controversial. 

People who test positive for a gene mutation may have increased risk for additional cancers, including pancreatic, , and others.  

The decisions about surveillance and risk-reducing surgery are complex

Initially, Ms. Campoverdi opted for increased surveillance: regular self- breast exams and yearly monitoring by healthcare providers with , breast  and .

Alejandra Campoverdi reported that:

"I felt like I was being proactive enough, but it was exhausting to constantly go to the doctor, not to mention anxiety-producing."

After several years of increased surveillance and discussions with her doctor, Alejandra decided to have a risk-reducing  mastectomy:

         "As my 39th birthday approached, it was time."

A surprise: preventive surgery uncovered early non-invasive breast cancer

"When I was wheeled into surgery in October 2018, I felt confident and empowered. I woke up feeling groggy but relieved that it was all behind me. I had no idea that the most shocking part was yet to come. Six days after my surgery, while I was still bandaged up and had drains coming out of my sides, I received an unexpected call from my doctor. She said the last thing I expected to hear: I had breast cancer."

Ms. Campoverdi was diagnosed with ductal carcinoma in situ (). is sometimes called " 0", non-invasive breast cancer. is a cluster of abnormal cells that have not spread beyond their origin in the lining of the breast ducts.

For Alejandra Campoverdi, her risk-reducing mastectomy led to early detection of a small, low-grade . Her treatment was straightforward:

"I would not need to do any more treatment—no chemo, no radiation, no hormonal treatment necessary. I never thought I’d have my decision validated like that. Turns out, I beat cancer before I knew I had it."

A voice for other previvors and women of color

There are documented disparities in breast cancer risk, prognosis and access to care for Latina women and other women of color.  

As a result of her personal history and experiences, Ms. Campoverdi founded the Well Woman Coalition as a voice for Latina women who have or are at risk for breast cancer. Ms. Campoverdi notes:

"I had good health care, my choice of doctors, and access to lots of information about my options. Yet this is not the case for many, including the women in my family. That's why I founded The Well Woman Coalition. Well Woman is an initiative to empower women of color to have agency over their own health and healing. The three principles of Well Woman are to arm yourself with information, make empowered choices, and to save your own life."

In partnership with Basser Center for at the University of Pennsylvania, The Well Woman Coalition has organized the “LATINX & ” campaign that focuses on information and Spanish-language materials for Latinas.

Lastly, Ms. Campoverdi points out:

"Treatment versus surveillance approaches are very personal, and each woman should decide what’s best for her. But if you have reason to believe that you may be at a higher risk of developing breast cancer or have several family members who have battled the disease, consider taking a test."

What does this mean for me?

  • If you have had breast cancer, have a family history of breast or other cancers, you may want talk to a genetic counselor or other health provider with experience in genetics. You may qualify for genetic testing.
  • If you test positive for a mutation in a gene associated with breast cancer, you should speak with your health care provider about risk-management options.

Share your thoughts on this XRAYS article by taking our brief survey.

Posted 6/6/19
 

Reference

Alejandra Campoverdi and Barbara Brody. "I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer." Health, May 18, 2019.
 

Disclosure

FORCE receives funding from industry sponsors, including companies that manufacture cancer drugs, tests and devices. All XRAYS articles are written independently of any sponsor and are reviewed by members of our Scientific Advisory Board prior to publication to assure scientific integrity.

This article is relevant for:

Young women of color with a BRCA mutation

This article is also relevant for:

previvors

people with ER/PR + cancer

Be part of XRAY:

Expert Guidelines
Expert Guidelines

NCCN guidelines recommend genetic counseling and testing for people without cancer who have the following family history:

  • A relative who has tested positive for an in a gene that increases cancer risk.
  • One or more first- or second-degree relatives with breast cancer and any of the following:
    • diagnosed at age 45 or younger
    • two separate breast cancers, with the first diagnosis at age 50 or younger
    • male breast cancer
  • One or more first- or second-degree relatives with:
    • colorectal cancer before age 50
    • endometrial cancer before age 50
    • ovarian, , primary peritoneal cancer
    • rare or childhood cancers
  • One or more first-degree relatives with:
    • or high-grade cancer
    • pancreatic cancer
  • Two or more relatives on the same side of the family diagnosed with any combination of the following at any age:
    • breast cancer
    • pancreatic cancer
    • cancer
    • melanoma
    • sarcoma
    • adrenal cancer
    • brain tumors
    • leukemia
    • endometrial cancer
    • thyroid cancer
    • kidney cancer
    • diffuse gastric cancer
    • colon cancer

Updated: 12/04/2021

Expert Guidelines
Expert Guidelines

The National Comprehensive Cancer Network (NCCN) provides breast cancer risk-management guidelines for people with and mutations. We recommend that you speak with a genetics expert who can review your personal and family history of cancer and help you to determine the best risk management plan. Note that our use of "men" and "women" refers to the sex you were assigned at birth.

Screening for women:

  • Beginning at age 18, be aware of how your breasts normally look and feel. Tell your doctor about any breast changes.
  • Beginning at age 25, have a doctor examine your breasts every 6-12 months.
  • Beginning at age 25, have an annual breast  with contrast (or  if  is unavailable).
  • Beginning at age 30 and continuing until age 75, have an annual and an annual breast with contrast.
  • After age 75, speak with your doctor about the benefits and risks of screening.

Risk reduction for women:

  • Speak with your doctor about of the advantages and disadvantages of risk-reducing mastectomy.
    • Research has shown that risk-reducing mastectomy can lower the chance of developing breast cancer in high-risk women by about 90%. Mastectomy has not been shown to help high-risk women live longer.
    • Because some breast tissue remains after mastectomy, some breast cancer risk also remains. 
  • Speak with your doctor about the benefits and risks of tamoxifen or other estrogen-blocking drugs to reduce your breast cancer risk. The benefits and risks may be different for women with or  mutations. Research on the benefit of these drugs to reduce breast cancer risk in women with  mutations has been mixed.

Risk management for men:

  • Beginning at age 35, learn how to do breast self-exams to check for breast changes.
  • Beginning at age 35, have a doctor examine your breasts every 12 months.
  • Beginning at age 50, consider an annual  (especially for men with mutations). 

Updated: 07/28/2023

Expert Guidelines
Expert Guidelines

The National Comprehensive Cancer Network (NCCN) provides guidelines for management of gynecologic cancer risk in people with and mutations. 

Prevention 

  • Risk-reducing removal of ovaries and , (known as salpingo-oophorectomy) is recommended between ages 35-40 for and 40-45 for and upon completion of childbearing.
    • Research studies show that removing the ovaries can increase survival for women with  mutations. 
    • Women should talk with their doctors about the effects of early menopause and options for managing them.
  • Women should talk with their doctors about the risks and benefits of keeping or removing their uterus (hysterectomy), including:
    • Women with a  mutation have an increased risk for a rare form of aggressive uterine cancer; hysterectomy removes this risk. 
    • For women considering hormone replacement after surgery, the presence or absence of a uterus can affect the choice of hormones used.
      • Estrogen-only hormone replacement is less likely to increase the risk for breast cancer, although it increases the risk for uterine cancer. Women who still have their uterus are typically given hormone replacement with both  and progesterone.
      • Adding progesterone to hormone replacement can protect against uterine cancer. However, the combination of these hormones may increase the risk for breast cancer more than alone. 
    • A medical history of fibroids or other uterine or cervical issues may justify a hysterectomy. 
  • Oral contraceptives (birth control pills) have been shown to lower the risk for ovarian cancer in women with  mutations. Research on the effect of oral contraceptives on breast cancer risk has been mixed. Women should discuss the benefits and risks of oral contraceptives for lowering ovarian cancer risk with their doctors. 
  • Removal of the  only () is being studied as an option for lowering risk in high-risk women who are not ready to remove their ovaries. Studies on the effects of are ongoing. At this time whether  lowers the risk for ovarian cancer in high-risk women remains unknown. 
    • Consider enrolling in a research study looking at this procedure to lower cancer risk.

Screening

  • There are no proven benefits to routine ovarian cancer screening using transvaginal  and a  blood test. However, some doctors still recommend this screening, starting at ages 30-35.
  • Women should be aware of the symptoms of gynecologic cancer and report abnormalities to their doctors. 

Updated: 08/06/2022

Peer Support
Peer Support

FORCE offers many peer support programs for people with inherited mutations. 

Updated: 08/06/2022

Find Experts
Find Experts

The following resources can help you locate a genetics expert near you or via telehealth.

Finding genetics experts

  • The National Society of Genetic Counselors website has a search tool for finding a genetic counselor by specialty and location or via telehealth. 
  • InformedDNA is a network of board-certified genetic counselors providing this service by telephone. They can also help you find a qualified expert in your area for face-to-face genetic counseling if that is your preference. 
  • Gene-Screen is a third-party genetic counseling group that can help educate, support and order testing for patients and their families. 
  • JScreen is a national program from Emory University that provides low-cost at-home genetic counseling and testing with financial assistance available.
  • Grey Genetics provides access to genetic counselors who offer genetic counseling by telephone. 
  • The Genetic Support Foundation offers genetic counseling with board-certified genetic counselors. 

Related experts

Genetics clinics

Other ways to find experts

Updated: 07/21/2023

Back to XRAY Home